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Abstract
Objective: Older people are vulnerable to zinc deficiency, which may impact
upon their mood. This randomised, placebo-controlled, double-blind interven-
tion study aimed to investigate the effect of oral zinc gluconate supplementation
(15 mg/d; 30 mg/d; and placebo) on subjective mood (affect) in older Europeans.
Subjects: Healthy volunteers (n 387) aged 55–87 years were recruited.
Setting: Volunteers in Rome (Italy; n 108) and Grenoble (France; n 91) were aged
70–87 years and those in Coleraine (Northern Ireland; n 93) and Clermont-Ferrand
(France; n 95) were aged 55–70 years.
Design: Mood was measured using the Positive and Negative Affect Scale on four
occasions per day over 4d at baseline, 3 and 6 months post-intervention.
Results: Mixed ANOVA indicated that neither positive nor negative affect altered in
response to zinc (15mg/d or 30mg/d) compared to placebo in either the 55–70 years
or the $70 years age group.










Psychological well-being is high on the list of public health
policy priorities, with the emphasis on prevention(1). Zinc is
an essential trace element(2) that is present in large quan-
tities in the brain and may be important for the maintenance
of psychological well-being. Zinc-containing neurons are
found in the forebrain interconnecting the cerebral cortex
(the cognitive or ‘thinking’ part of the brain) and the limbic
system (the affective or ‘feeling’ part of the brain)(3). The
synaptic vesicles of the hippocampus and amygdala, which
are both limbic structures, contain particularly large quan-
tities of zinc(4), implying a role for zinc in the control of
emotion. Zinc-containing neurons are receptive to gluta-
mine, an amino acid neurotransmitter that is excitatory and
that exerts a neuromodulatory effect on post-synaptic glu-
tamate receptors within the hypothalamic–pituitary–adrenal
axis (HPA) system(4,5). Rodent studies have indicated that
this action occurs mainly through the hippocampus synap-
ses, which are involved in the regulation of the HPA sys-
tem(6–11). Zinc may also be involved in the control of the
serotonergic system(5,12,13). Zinc has been shown to increase
the density of 5-HT serotonin receptors in the hippocampus
and frontal cortex in rats(12). Post-mortem evidence suggests
that zinc may have a role in the nutritional methylation
processes(14) that are also believed to be important in the
regulation of mood(15). The human central nervous system
appears to be adversely affected by zinc deficiency. Lower
serum zinc is associated with depression(16–20) and a marker
of treatment resistance in clinical depression(20,21). Lower
serum zinc is also associated with disordered beha-
viour(22–24). Zinc supplementation has also been shown to
ameliorate depression in clinical groups(25,26). There is an
apparent dearth of human studies of zinc and well-being in
healthy (non-clinical) groups. Among the few studies of
healthy individuals is a recent cross-sectional study of
Korean women (n 570), which indicated that among other
nutrients and trace elements, lower dietary zinc intake was
associated with higher stress scores on the short version of
the Psychological Well-being Index(27). A recent double-
blind, placebo-controlled trial of zinc (7mg/d) in young
women (n 30) found reduced scores on the anger/hostility
and depression scales of the Profile of Mood States(28).
These studies imply a link between zinc and psychological
well-being in health. There appear to be no existing trials of
zinc and well-being or mood in men and/or older people.
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Europe and much of the industrialised Western world
has a growing ageing population(1), hence, the need to
maintain psychological well-being and quality of life in
this vulnerable age group. The elderly are particularly at
risk of zinc deficiency, the likelihood of which increases
with age(29–33) as a result of a range of physiological,
social, psychological and economic factors(34) that may be
associated with the decreased consumption of zinc-rich
foods(35–38). Dysregulation of the HPA system is associated
with the increased risk of CVD, diabetes, cancer, inflam-
matory conditions and neurodegenerative disorders(39).
HPA system activity has been shown previously to be
related to positive affect (PA) in the elderly(40). Maintaining
a higher PA in old age, therefore, is potentially important
for general health and well-being as well as disease pre-
vention(41) in otherwise healthy older people. Assuming
that zinc exerts a neuromodulatory effect through the HPA
system, optimising zinc status in older people, therefore, is
likely to have far-reaching benefits to psychological health.
Yet, there do not appear to be any previous studies that
have considered zinc and affect in healthy older indivi-
duals. Existing evidence for benefits of zinc to psycholo-
gical well-being is mainly derived from post hoc
investigation using psychiatric in-patients. Trials in healthy
populations are necessary to further our understanding of
how dietary constituents such as zinc impact upon health
and well-being and to provide evidence to support or
refute potential functional claims for zinc-rich food pro-
ducts. Trials in healthy individuals are especially important,
given the widespread and increasing use of self-prescribed
nutrient supplements by the older public(42). The Zenith
Study aimed to assess the effects of zinc supplementation
in the normal healthy older population. It was necessary,
therefore, to intervene with zinc at dosages that would be
available for purchase over the counter without prescrip-
tion. This randomised, placebo-controlled, double-blind
intervention study reports the effect upon PA and negative
affect (NA) of zinc (15mg/d and 30mg/d) supplements
administered orally over 6 months compared to placebo in
healthy 55–70-year-olds recruited to the Zenith Study in
Coleraine and Clermont-Ferrand and $70-year-olds in
Grenoble and Rome. This research meets an imperative for
controlled supplementation trials investigating the effect
of zinc on psychological well-being in the older popula-
tion. It is hypothesised that zinc supplementation will alter
subjective affective state compared to placebo.
Methods
The Zenith Study was a randomised, double-blind,
placebo-controlled intervention trial of zinc in older
adults, which was conducted in four European centres.
Ethics approval for the study was obtained from recog-
nised research centres in each country. Informed, written
consent was obtained from each participant.
Sampling
Volunteers were outreached in different ways includ-
ing through local television and radio broadcast, posters
and through leaflets distributed in supermarkets, clubs that
free-living elderly people frequently visit, health centres,
and family doctors. Prospective volunteers then initiated
contact with the research group who then arranged an
appointment for the preliminary screening. The volunteers
were screened first by clinical examination, anthropometry,
smoking and alcohol consumption, cognitive impairment,
depression and biochemistry profiles. Those selected for
inclusion in the study were apparently healthy, not mor-
bidly obese and with a BMI of between 20kg/m2 and
30kg/m2(43). Only those who had no evidence of dementia,
as indicated by a score .23 in the Mini Mental State
Examination (MMSE) test(44), were included. Volunteers
were screened for depression using the Geriatric Depres-
sion Scale (GDS)(45). The GDS has been validated as a
screening tool for depression against the DSM-IV criteria
according to which only those scoring $6 can be con-
sidered not clinically depressed(46). Those with a score
of #5 were included. Participants were also excluded if
they had a positive serology for HIV or hepatitis C, if
they smoked more than ten cigarettes per day; consumed
alcohol .30g/d for men and .20g/d for women; had
unusual dietary habits (vegetarianism and veganism); used
a mineral supplement in the 3 months preceding the study;
used more than three drugs daily if aged 55–70 years; used
more than four drugs daily if over 70 years; used drugs
including antidepressants, laxatives and hormone replace-
ment therapy; or had a pathological disease (cancer, diabetes,
insufficient renal or hepatic performance, malabsorption and
inflammatory chronic pathologies). Complete details about
screening and recruitment processes have been described
previously by Polito et al.(47).
Serum zinc
Unfortunately, there is no single accurate measure of zinc
status(48,49). For the purpose of the present study, serum
zinc was taken as a putative indicator of current zinc
status(50). Fasting blood samples were obtained for the
zinc assay in the morning. Blood samples for the zinc
assay were collected via venepuncture by qualified the
phlebotomists, using trace element-free VacutainerR
tubes (Becton, Dickinson and company Ltd, Oxford, UK).
The blood sample was taken in the morning after a 12 h
fast by the participants. Immediately after drawing, the
blood samples were kept on ice, and then centrifuged
at 1000g for 15 min at 48C. Serum zinc was immediately
isolated, aliquoted and stored at 2808C. Serum zinc
concentrations at baseline were determined at INRA
Clermont-Ferrand, France, by flame atomic absorption
spectrometry using a Perkin-Elmer 560 instrument (Perkin
Elmer, Cambridge, UK)(50). Internal quality control was
checked using SeronormR trace element serum (SeroR ,
Billingstad, Norway).
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Dietary zinc
Dietary zinc intake was assessed at baseline by means of
a semi-structured standardised 4 d food diary over two
weekdays and two weekend days consecutively, which
included estimates of portion size, the brand name of the
product and/or the recipe if cooked from fresh. The
information in the food diaries was analysed using the
NetWISP version 3?0 (Tinuviel Software Anglesey, UK)
database. A full account of the dietary assessment pro-
cedure has been provided previously by Polito et al.(51).
Positive and Negative Affect Scale
The Positive and Negative Affect Schedule (PANAS) is a
well-validated twenty-item self-reported psychometric
measure of subjective mood developed by Watson et al.(52).
Watson and Tellegen(53) proposed that there are two distinct
dimensions of mood state, PA and NA, which together
account for over two-thirds of the variance in mood. PA
is associated with feelings of alertness, enthusiasm and
happiness and NA with displeasure and dissatisfaction(54).
PANAS scores have been shown to correlate with salivary
cortisol levels(40) and whole blood serotonin levels in
healthy individuals(55,56). The scales have been found to
have high internal consistency, with Cronbach’s a ranging
from 0?84 to 0?87 for the NA scale and 0?84 to 0?90 for the
PA scale(57). Repeated measures of affect were taken during
the week before the centre visit, including one further
measure taken on the morning of testing. The participants
were asked to complete four self-reported PANAS ques-
tionnaires daily (on rising, after lunch, after dinner, and
before going to bed) for four consecutive days at baseline,
3 and 6 months. The scale took approximately 2min to
complete. The items were: interested; distressed; excited;
upset; strong; guilty; scared; hostile; enthusiastic; proud;
irritable; alert; ashamed; inspired; nervous; determined;
attentive; jittery; active; and afraid. Responses to the
PANAS were recorded on a 5-point Likert scale ranging
from ‘not at all’ 5 1 to ‘extremely’ 5 5. A score for each scale
was obtained by summing item scores.
Intervention
Eligible volunteers were randomly assigned to three
groups to receive either 15 mg/d or 30 mg/d zinc gluco-
nate or placebo orally. Zinc capsules were issued in dated
pillboxes at baseline and at 3 and 6 months into the
supplementation phase. The participants were instructed
to swallow the capsules with breakfast. The degree of
compliance was estimated by collecting the number of
returned capsules at 3 and 6 months. Compliance was
tested and was found to be .98 % for all groups.
Data analysis
The mood data were analysed using a mixed ANOVA.
Separate analyses were computed for the 55–70-year-olds
(n 188; from Coleraine and Clermont-Ferrand) and for the
$70-year-olds (n 199; from Grenoble and Rome). There
were three between-group factors (sex, centre and
treatment) and one repeated measure (baseline, 3 and
6 months post-intervention) included in each ANOVA.
Mean PA and NA were treated as separate dependent
variables, which also required separate ANOVAs. In the
absence of relevant previous studies in this area, a con-
servative value of f 2 5 0?025 for effect sizes was adopted.
For the mood scale it was assumed that the correlations
among each of the repeated measures were 0?42 (taken
from the PANAS manual). Power calculations were per-
formed using GPOWER general power analysis computer
program (G*Power, Bonn, Germany)(58). With a 5 0?05
and assuming 180 participants within each age group
(55–70 and $70 years), the power values for the
between-groups and within-groups and interaction
effects were 0?36, 0?99 and 0?81, respectively. As the
interaction effects (particularly the treatment–time interac-
tion) were of prime concern in the present study,
the sample sizes for both the younger (n 188) and the older
(n 199) age groups were regarded as satisfactory. Sig-
nificance was set at P , 0?05. The Statistical Package for
Social Sciences statistical software package version 11?5
(SPSS UK Ltd., Feltham, UK) was used for statistical analysis.
Results
Approximately 10–15 % of those who initiated contact
were included in the study. Equal proportions of healthy
male and female older volunteers were recruited from
four European centres. Coleraine, Northern Ireland (n 93)
and Clermont-Ferrand, France (n 95) recruited partici-
pants aged 55–70 years, while Rome, Italy (n 108) and
Grenoble, France (n 91) recruited participants who were
.70 years of age. In total, 387 participants successfully
completed the trial (Table 1). A full description of the
sample characteristics has been provided elsewhere by
Simpson et al.(59).
Baseline measures
Neither sex nor age differed between the treatment groups.
The younger (55–70 years) age group comprised a higher
proportion (84%) of professional occupations than the
older ($70 years) age group (68%). A higher proportion of
those in the younger age group (96%) than the older age
group (35%) were educated to the tertiary level. Neither
social class nor educational level differed between the
treatment groups. There were no apparent differences by
age group or treatment group in dietary zinc intake at
baseline. There were no differences in MMSE or (GDS)
scores by age group or treatment condition(60).
Serum zinc
Mean serum zinc was within the normal range
(11–18 mmol/l)(61) for the placebo (mean 5 13?20 (SD
1?69) mmol/l), 15 mg (mean 5 13?28 (SD 1?84) mmol/l) and
30 mg (mean 5 13?13 (SD 1?63) mmol/l) supplemented
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groups at baseline and remained so throughout the inter-
vention period. Serum zinc increased over time (F (4197) 5
11?021, P 5 0?000) in both the 15mg (mean 5 13?99 (SD
2?47) mmol/l; P 5 0?018) and 30mg (mean 5 15?03 (SD 3?17)
mmol/l; P 5 0?000) supplemented groups compared to
placebo (mean 5 13?05 (SD 1?66) mmol/l) suggesting com-
pliance with the intervention. Serum zinc concentrations in
response to zinc (30mg) were higher among those recruited
in Rome (mean 5 16?26 (SD 3?41) mmol/l) than Grenoble
(mean513?64 (SD 2?21)mmol/l) post-intervention (F (4197)5
3?526, P 5 0?008).
Affect (the Positive and Negative Affect Scale)
and zinc
There were no treatment (15 mg/d zinc; 30 mg/d zinc;
or placebo) 3 time (baseline; 3 months; or 6 months post-
intervention) or interaction effects, indicating that the
treatment had no differential effects on affect (PANAS)
over time. For NA among the 55–70-year-olds, the inter-
action effect was F (4340) 5 1?56, P 5 0?185 (Table 1) and
for the $70-year-olds, F (4372) 5 0?466, P 5 0?761 (Table 2).
Interaction effects for PA among the 55–70-year-olds
were F (4340) 5 0?37, P 5 0?833 (Table 2) and among the
$70-year-olds were F (4372) 5 1?32, P 5 0?261 (Table 3).
None of the triple interaction effects involving treatment and
time were significant.
Centre and affect (the Positive and Negative
Affect Scale)
There was a significant treatment 3 centre interaction effect
for NA among the $70-year age group (F (1186) 5 3?73,
P 5 0?025). For the placebo, 15mg/d and 30mg/d treat-
ment groups, the means were 11?45, 13?43 and 11?94,
respectively, for Rome and 13?06, 12?83 and 14?38,
respectively, for Grenoble. For Grenoble, the trend for NA
was U-shaped showing a decrease at 3 months into the
intervention and returning to baseline at 6 months.
For Rome, the trend for NA was an inverted U-shape
such that NA was increased at 3 months into the inter-
vention and returning to baseline at 6 months. There
were no significant interactions between treatment and
centre for PA in either the 55–70-year or $70-year age
group.
Gender and affect (the Positive and
Negative Affect Scale)
With the exception of a significant gender 3 centre
interaction effect for NA among the 55–70-year-olds
(F(1170) 5 4?71, P 5 0?031), there were no significant
main effects or interaction effects for gender. The sig-
nificant gender 3 centre interaction effect was such that
male volunteers reported higher NA than female volun-
teers in the Coleraine sample (mean 5 12?00 and 11?39,
Table 1 Sociodemographic variables for each region, given as percentages
Northern Ireland (55–70 years) Clermont-Ferrand (55–70 years) Rome (70–85 years) Grenoble (70–87 years)
Variables Mean SD Mean SD Mean SD Mean SD
Age (years) 62?4 4?5 61?3 4?3 74?5 4 74?2 3?5
% % % %
Sex
Male 48 51 52 52
Female 52 49 48 48
Education
Primary 99 100 99 100
Secondary 91 75 76 66
Tertiary 41 35 20 15
No education 1 – 1 –
Social class
Professional 54 30 15 41
Skilled 33 60 58 53
Unskilled 8 10 27 6
Unclassified 4 – – –
Total participants5387: Northern Ireland 5 93; Clermont-Ferrand 5 95; Rome 5 108; and Grenoble 5 91.
Table 2 PANAS scores for each treatment group (55–70-year-olds/Coleraine and Clermont-Ferrand) over time (n 188)
Positive affect Negative affect
Placebo Zn (15 mg) Zn (30 mg) Placebo Zn (15 mg) Zn (30 mg)
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Baseline 26?14 4?83 28?05 5?49 28?40 5?70 11?66 2?63 11?72 2?11 11?44 2?00
3 months 27?05 4?21 28?59 5?85 29?47 5?76 11?92 2?70 12?24 3?67 11?46 1?99
6 months 26?86 5?20 28?70 6?09 29?06 5?54 11?84 2?89 12?22 3?30 11?22 1?95
PANAS, Positive and Negative Affect Score.
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respectively), whereas the reverse was true in the Clermont-
Ferrand sample (mean 5 11?48 and 12?14).
Discussion
Studies of clinically depressed(18–24) and healthy(27,28)
groups have suggested a link between zinc status and
psychological well-being. Given evidence to suggest that
for a multiplicity of reasons, ageing can be associated
with zinc depletion(31), it was hypothesised that supple-
mented zinc would enhance mood in older people. It
was, therefore, surprising to find no alteration in PA or NA
in response to zinc (15 mg/d or 30 mg/d) compared to
placebo in either the younger (55–70 years) or the older
($70 years) age group, who had lower PA than the
younger age group at baseline(61). Both NA and PA were
unaffected by zinc supplementation in either age group.
In the older age group ($70 years), NA increased among
those in Rome and decreased among those in Grenoble
3 months into the intervention and returned to baseline in
both groups at 6 months. This trend is difficult to explain.
Although serum zinc was higher among those in Rome
than Grenoble at 3 months, serum zinc is not an accurate
indicator of zinc status and could have been altered in
response to a range of factors unrelated to affect(49).
Increased serum zinc concentrations post-treatment,
however, suggest good compliance with the intervention
in both groups. The PANAS is a well-validated subjective
(self-reported) psychometric measure of affect(52), which
has been widely used and previously used in other
studies involving elderly adults(62). The PANAS has also
been shown to correlate with the biochemical markers of
affect(40,55,56). This correlation indicates that although
the scales measure subjective affect, the data generated
can be considered sensitive to corresponding changes in
neurochemical activity. The PANAS can, therefore, be
assumed to have good concurrent validity for the mea-
surement of affect. Although the PA data collected for the
present study agree with those of the established norms,
the NA scores appear to be less than those suggested by
established norms for older people(52). The relatively low
NA reported by our sample at baseline may explain the
lack of change in NA following zinc supplementation.
The apparent lack of change in affect in response to zinc
could also be because the participants were zinc replete(50).
Screening procedures were stringent and care was taken to
recruit only physically and psychologically healthy older
people to the Zenith Study. Health and well-being tend to
be confounded with social factors. It is possible that in
selecting only healthy individuals, those from socio-eco-
nomically deprived segments of society have been exclu-
ded. That our sample was biased towards the higher social
classes and those who had spent a relatively longer period
in education (Table 1) may also explain the apparently
good psychological well-being among our sample and lack
of response to the intervention. The participants, by virtue
of having volunteered, may not be entirely representative of
the general population, potentially limiting the degree to
which the findings can be extrapolated to the general older
population. Those who have spent longer periods of time
in education and those in more privileged social classes
tend to have lower mortality and morbidity(1) and may,
therefore, also have a greater chance of being recruited to
such studies.
Conclusion
The present study seems to be the first randomised,
double-blind, placebo-controlled intervention trial inves-
tigating the impact of supplemented zinc upon affect in
healthy older adults. Intervention outcomes were asses-
sed using the PANAS, which is a well-validated subjective
(self-reported) psychometric measure of affect. The study
was also strong in that it used a relatively large sample
comprising late middle-aged and elderly individuals from
both northern and southern European populations with
adequate power with which to uphold the null hypoth-
esis and within which sex and cultural effects were con-
trolled. These data suggest that zinc supplementation at
considered 15 mg/d or 30 mg/d does not alter mood in
healthy elderly European adults.
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